A Phase 2 Multi-center, Randomized, Double Blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of T-817MA in Patients With Mild to Moderate Alzheimer's Disease

Trial Profile

A Phase 2 Multi-center, Randomized, Double Blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of T-817MA in Patients With Mild to Moderate Alzheimer's Disease

Completed
Phase of Trial: Phase II

Latest Information Update: 20 Jul 2017

At a glance

  • Drugs Edonerpic (Primary)
  • Indications Alzheimer's disease
  • Focus Therapeutic Use
  • Sponsors Toyama Chemical
  • Most Recent Events

    • 20 Jul 2017 Results presented at the Alzheimer's Association International Conference 2017
    • 19 Jul 2017 Results published in a FUJIFILM Corporation Media Release.
    • 19 Jul 2017 Primary endpoint has not been met. (The primary objective is to evaluate the efficacy of T-817MA as measured by ADAS-cog and ADCS-CGIC., according to a FUJIFILM Corporation media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top